Related Experiment Video
Updated: Sep 16, 2025
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS
Abstract:
Colorectal cancer (CRC) remains a significant clinical challenge, with a 5-year survival rate of 10%. Over half of all CRCs harbor mutations in the KRAS gene, leading to poor response to standard therapy. This underscores the crucial need for novel therapeutics targeting KRAS and overcoming the growing barrier of resistance. To address these critical challenges, we conducted a high-throughput screen to identify small molecules that synergize with KRAS G12D inhibitor MRTX1133 against CRC. Through screening a 2,652 kinase inhibitor library, we discovered that Osimertinib and its analogs strongly synergize with MRTX1133 against both parental and MRTX1133-resistant cells. The top compound from the screen, NT-1, is a chemical analog of Osimertinib. NT-1 strongly synergized with MRTX1133 to suppress EGFR/MAPK signaling and induce apoptosis in an MRTX1133-resistant patient-derived organoid model of CRC. We present novel small molecule combinations with the potential to overcome the limitations of MRTX1133 with direct clinical translational applications.
One Sentence Summary:
High throughput screening and validation in colon cancer PDOs identifies novel KRAS inhibitor combinations with potential for clinical translation.
Insights
Novel drug combinations show promise for treating colorectal cancer (CRC) resistant to KRAS inhibitors. Osimertinib analogs synergize with MRTX1133, overcoming resistance and inducing cancer cell death.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Colorectal cancer (CRC) presents a significant clinical challenge with a low 5-year survival rate.
- KRAS mutations are prevalent in over half of CRCs, conferring resistance to standard therapies.
- Targeting KRAS and overcoming resistance are critical for improving CRC treatment outcomes.
Purpose of the Study:
- To identify small molecules that synergize with the KRAS G12D inhibitor MRTX1133 against CRC.
- To discover novel therapeutic strategies for overcoming resistance to KRAS-targeted therapies.
- To evaluate the clinical translational potential of identified drug combinations.
Main Methods:
- Conducted a high-throughput screen of a 2,652 kinase inhibitor library.
- Validated synergistic effects of Osimertinib analogs with MRTX1133 in parental and resistant CRC cells.
- Utilized patient-derived organoid models to assess drug efficacy and signaling pathway modulation.
Main Results:
- Osimertinib and its analogs demonstrated strong synergy with MRTX1133 against both sensitive and resistant CRC cells.
- The identified compound NT-1, an Osimertinib analog, synergized with MRTX1133 to suppress EGFR/MAPK signaling.
- Combination therapy induced apoptosis in a resistant CRC patient-derived organoid model.
Conclusions:
- Novel small molecule combinations, including Osimertinib analogs and MRTX1133, can overcome resistance in KRAS-mutant CRC.
- These combinations effectively suppress key oncogenic signaling pathways and induce cancer cell death.
- The findings support the direct clinical translational application of these novel therapeutic strategies for CRC treatment.
More Related Videos
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016